Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Intangible asset amortization expense for the years ended December 31, 2018 through 2022 is estimated to be as follows:



(In millions)
2018	$	1,450
2019	1,358
2020	1,211
2021	1,131
2022	1,060

Changes in carrying amount of goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2017 and 2016 are as follows:



(In millions)	North America Segment			Europe Segment			Rest of World Segment			Total
Balance at December 31, 2015:
Goodwill	$	3,178.7		$	1,000.5		$	1,585.9		$	5,765.1
Accumulated impairment losses	(385.0		)	—			—			(385.0		)
	2,793.7			1,000.5			1,585.9			5,380.1
Acquisitions and measurement period adjustments ⁽¹⁾	818.6			2,993.0			190.6			4,002.2
Foreign currency translation	(6.9		)	(134.4		)	(9.1		)	(150.4		)
	3,605.4			3,859.1			1,767.4			9,231.9
Balance at December 31, 2016:
Goodwill	3,990.4			3,859.1			1,767.4			9,616.9
Accumulated impairment losses	(385.0		)	—			—			(385.0		)
	3,605.4			3,859.1			1,767.4			9,231.9
Acquisitions	92.2			—			—			92.2
Reclassifications⁽²⁾	(200.1		)	382.2			(182.1		)	—
Measurement period adjustments	—			7.7			—			7.7
Divestiture	—			(1.3		)	—			(1.3		)
Foreign currency translation	52.1			719.4			103.7			875.2
	3,549.6			4,967.1			1,689.0			10,205.7
Balance at December 31, 2017:
Goodwill	3,934.6			4,967.1			1,689.0			10,590.7
Accumulated impairment losses	(385.0		)	—			—			(385.0		)
	$	3,549.6		$	4,967.1		$	1,689.0		$	10,205.7

Components of intangible assets

Intangible assets consist of the following components at December 31, 2017 and 2016:



(In millions)	Weighted Average Life (Years)	Original Cost		Accumulated Amortization		Net Book Value
December 31, 2017
Amortized intangible assets:
Product rights and licenses	15	$	19,762.9	$	5,373.7	$	14,389.2
Patents and technologies	20	116.6		113.1		3.5
Other ⁽¹⁾	6	459.2		419.3		39.9
		20,338.7		5,906.1		14,432.6
In-process research and development		813.2		—		813.2
		$	21,151.9	$	5,906.1	$	15,245.8
December 31, 2016
Amortized intangible assets:
Product rights and licenses	15	$	16,968.4	$	3,585.7	$	13,382.7
Patents and technologies	20	116.6		108.5		8.1
Other ⁽¹⁾	6	465.9		330.0		135.9
		17,550.9		4,024.2		13,526.7
In-process research and development		921.1		—		921.1
		$	18,472.0	$	4,024.2	$	14,447.8

____________


⁽¹⁾	Other intangibles consist principally of customer lists, contractual rights and other contracts.

Product rights and licenses by therapeutic category

Product rights and licenses are primarily comprised of the products marketed at the time of acquisition. These product rights and licenses relate to numerous individual products, the net book value of which, by therapeutic franchise, is as follows:



(In millions)	December 31, 2017		December 31, 2016
Central Nervous System and Anesthesia	$	2,453.7	$	2,172.0
Dermatology	2,393.0		2,070.2
Gastroenterology	2,050.0		1,906.2
Diabetes and Metabolism	1,425.6		1,395.7
Cardiovascular	1,779.5		1,718.0
Respiratory and Allergy	1,769.5		1,691.0
Infectious Disease	494.8		490.6
Oncology	380.1		413.4
Women's Healthcare	371.4		371.4
Immunology	301.5		284.9
Other ⁽¹⁾	970.1		869.3
	$	14,389.2	$	13,382.7

Finite-lived Intangible Assets Amortization Expense [Table Text Block]

Amortization expense and intangible asset impairment charges, which are included as a component of amortization expense, which is classified primarily within cost of sales in the Consolidated Statements of Operations, for the years ended December 31, 2017, 2016 and 2015 was as follows:



	Year ended December 31,
(In millions)	2017		2016		2015
Intangible asset amortization expense	$	1,437.4	$	1,195.3	$	814.7
Intangible asset impairment charges	80.8		68.3		31.3
Total intangible asset amortization expense (including impairment charges)	$	1,518.2	$	1,263.6	$	846.0